Andrea De Maria
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrea De Maria has a total of 303 co-authors. Here are the top co-authors by number of shared publications:
- Federica Bozzano
Centro di Eccellenza per la Ricerca Biomedica, Universita' di Genova, Genova, Italy
15 shared publications Lorenzo Moretta
Tumor Immunology Unit, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
11 shared publications- Antonio Di Biagio
University of Genoa
9 shared publications Francesco Marras
Center for Excellence in Biomedical Research, University of Genova, Genoa, Italy
9 shared publications- Chiara Dentone
Clinica Malattie Infettive, IRCCS Ospedale Policlinico San Martino
6 shared publications Federica Bozzano
Laboratorio Diagnostico di Autoimmunologia, IRCCS Ospedale Policlinico San Martino, Genova, Italy
6 shared publications
Latest Publications
- Open Access
- 28 March 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Undetectable unintegrated HIV-DNA in persons with HIV: frequency and determinants
Background: Despite suppressive antiretroviral therapy (ART), HIV-1 persists in infected cells as integrated proviral DNA and as more labile unintegrated DNA forms (uDNA). The presence of uDNA has been proposed as a surrogate marker of recent infection events occurring below the detection limits of plasma HIV-1 RNA assays. The aim of this study was to evaluate the performance of an assay for the quantification of uDNA in peripheral whole blood of people with HIV (PWH), with the intent of identifying individuals with no evidence of recent infection events, defined as undetectable uDNA, and to characterize associated clinical and immunological factors. Methods: Total and unintegrated HIV-1 DNA were quantified by real-time PCR in whole blood samples from 87 chronically treated PWH. Samples were derived from a real-world, retrospective cohort and reflected the antiretroviral regimens actually received by patients over time. Clinical, virological, and immunological parameters were analyzed in relation to uDNA detectability. Results: Overall, uDNA was quantifiable in 11/87 (13%) samples, detectable below the assay quantification limit in 52/87 (60%), and undetectable (target not detected) in 24/87 (28%). Undetectable uDNA was associated with higher CD4⁺ T-cell nadir, higher current CD4⁺ T-cell counts, and lower total HIV-1 DNA levels. In multivariable analysis, CD4⁺ T-cell nadir was the only factor independently associated with uDNA undetectability ( p = 0.001). Antiretroviral regimen characteristics were not independently associated with uDNA detectability. Conclusions: A substantial proportion of chronically treated PWH exhibited undetectable uDNA in peripheral blood. The uDNA measurement provides complementary information to plasma HIV-1 RNA and CD4⁺ T-cell counts and may help identify individuals with no evidence of recent infection events and higher immunological fitness. These findings support the potential utility of uDNA quantification as a biomarker of HIV-1 reservoir dynamics in real-world clinical settings.
- 28 March 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Open AccessUndetectable unintegrated HIV-DNA in persons with HIV: frequency and determinants
Background: Despite suppressive antiretroviral therapy (ART), HIV-1 persists in infected cells as integrated proviral DNA and as more labile unintegrated DNA forms (uDNA). The presence of uDNA has been proposed as a surrogate marker of recent infection events occurring below the detection limits of plasma HIV-1 RNA assays. The aim of this study was to evaluate the performance of an assay for the quantification of uDNA in peripheral whole blood of people with HIV (PWH), with the intent of identifying individuals with no evidence of recent infection events, defined as undetectable uDNA, and to characterize associated clinical and immunological factors. Methods: Total and unintegrated HIV-1 DNA were quantified by real-time PCR in whole blood samples from 87 chronically treated PWH. Samples were derived from a real-world, retrospective cohort and reflected the antiretroviral regimens actually received by patients over time. Clinical, virological, and immunological parameters were analyzed in relation to uDNA detectability. Results: Overall, uDNA was quantifiable in 11/87 (13%) samples, detectable below the assay quantification limit in 52/87 (60%), and undetectable (target not detected) in 24/87 (28%). Undetectable uDNA was associated with higher CD4⁺ T-cell nadir, higher current CD4⁺ T-cell counts, and lower total HIV-1 DNA levels. In multivariable analysis, CD4⁺ T-cell nadir was the only factor independently associated with uDNA undetectability ( p = 0.001). Antiretroviral regimen characteristics were not independently associated with uDNA detectability. Conclusions: A substantial proportion of chronically treated PWH exhibited undetectable uDNA in peripheral blood. The uDNA measurement provides complementary information to plasma HIV-1 RNA and CD4⁺ T-cell counts and may help identify individuals with no evidence of recent infection events and higher immunological fitness. These findings support the potential utility of uDNA quantification as a biomarker of HIV-1 reservoir dynamics in real-world clinical settings.
- Open Access
- 7 June 2024
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 44 (6) , 1-16
Evaluation of Frequency of CMV Replication and Disease Complications Reveals New Cellular Defects and a Time Dependent Pattern in CVID Patients
Purpose: Common Variable Immunodeficiency (CVID) is characterized by hypogammaglobulinemia and failure of specific antibody production due to B-cell defects. However, studies have documented various T-cell abnormalities, potentially linked to viral complications. The frequency of Cytomegalovirus (CMV) replication in CVID cohorts is poorly studied. To address this gap in knowledge, we set up an observational study with the objectives of identifying CVID patients with active viraemia (CMV, Epstein-Barr virus (EBV)), evaluating potential correlations with immunophenotypic characteristics, clinical outcome, and the dynamic progression of clinical phenotypes over time. Methods: 31 CVID patients were retrospectively analysed according to viraemia, clinical and immunologic characteristics. 21 patients with non CVID humoral immunodeficiency were also evaluated as control. Results: Active viral replication of CMV and/or EBV was observed in 25% of all patients. CMV replication was detected only in CVID patients (16%). CVID patients with active viral replication showed reduced HLA-DR+ NK counts when compared with CMV-DNA negative CVID patients. Viraemic patients had lower counts of LIN−DNAMbright and LIN−CD16+ inflammatory lymphoid precursors which correlated with NK-cell subsets. Analysis of the dynamic progression of CVID clinical phenotypes over time, showed that the initial infectious phenotype progressed to complicated phenotypes with time. All CMV viraemic patients had complicated disease. Conclusion: Taken together, an impaired production of inflammatory precursors and NK activation is present in CVID patients with active viraemia. Since “Complicated” CVID occurs as a function of disease duration, there is need for an accurate evaluation of this aspect to improve classification and clinical management of CVID patients.
- 7 June 2024
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 44 (6) , 1-16
Open AccessEvaluation of Frequency of CMV Replication and Disease Complications Reveals New Cellular Defects and a Time Dependent Pattern in CVID Patients
Purpose: Common Variable Immunodeficiency (CVID) is characterized by hypogammaglobulinemia and failure of specific antibody production due to B-cell defects. However, studies have documented various T-cell abnormalities, potentially linked to viral complications. The frequency of Cytomegalovirus (CMV) replication in CVID cohorts is poorly studied. To address this gap in knowledge, we set up an observational study with the objectives of identifying CVID patients with active viraemia (CMV, Epstein-Barr virus (EBV)), evaluating potential correlations with immunophenotypic characteristics, clinical outcome, and the dynamic progression of clinical phenotypes over time. Methods: 31 CVID patients were retrospectively analysed according to viraemia, clinical and immunologic characteristics. 21 patients with non CVID humoral immunodeficiency were also evaluated as control. Results: Active viral replication of CMV and/or EBV was observed in 25% of all patients. CMV replication was detected only in CVID patients (16%). CVID patients with active viral replication showed reduced HLA-DR+ NK counts when compared with CMV-DNA negative CVID patients. Viraemic patients had lower counts of LIN−DNAMbright and LIN−CD16+ inflammatory lymphoid precursors which correlated with NK-cell subsets. Analysis of the dynamic progression of CVID clinical phenotypes over time, showed that the initial infectious phenotype progressed to complicated phenotypes with time. All CMV viraemic patients had complicated disease. Conclusion: Taken together, an impaired production of inflammatory precursors and NK activation is present in CVID patients with active viraemia. Since “Complicated” CVID occurs as a function of disease duration, there is need for an accurate evaluation of this aspect to improve classification and clinical management of CVID patients.
- Open Access
- 8 February 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1332781
CD34+DNAM-1brightCXCR4+ haemopoietic precursors circulate after chemotherapy, seed lung tissue and generate functional innate-like T cells and NK cells
Background: There is little information on the trajectory and developmental fate of Lin-CD34+DNAM-1bright CXCR4+ progenitors exiting bone marrow during systemic inflammation.Objective: To study Lin-CD34+DNAM-1bright CXCR4+ cell circulation in cancer patients, to characterize their entry into involved lung tissue and to characterize their progenies.Methods: Flow cytometric analysis of PBMC from 18 patients with lung cancer on samples collected immediately before the first and the second treatment was performed to study Lin-CD34+DNAM-1bright CXCR4+ precursors. Precursors were purified (>99%) and cultured in vitro from all patients. Paired PBMC and tissue samples from patients undergoing tumor resection were analyzed by flow cytometry to assess tissue entry and compare phenotype and developmental potential of Lin-CD34+DNAM-1bright CXCR4+ cells in both compartments.Results: Significant circulation of Lin-CD34+DNAM-1bright CXCR4+ precursors was observed 20d after the first treatment. Precursors express CXC3CR1, CXCR3, CXCR1 consistent with travel towards inflamed tissues. Flowcytometric analysis of lung tissue samples showed precursor presence in all patients in tumor and neighboring uninvolved areas. Successful purification and in vitro culture from both blood and lung tissue generates a minor proportion of maturing NK cells (85%) of α/β T-progenies with innate-like phenotype expressing NKG2D,NKp30,DNAM-1. Innate-like maturing T-cells in vitro are cytotoxic, can be triggered via NKR/TCR co-stimulation and display broad spectrum Th1,Th2 and Th1/Th17 cytokine production.Conclusion: In advanced stage lung cancer CD34+DNAM-1brightCXCR4+ inflammatory precursors increase upon treatment, enter involved tissues, generate functional progenies and may thus represent an additional player contributing to immune balance in the highly SDF-1/CXCR4-biased pro-metastatic tumor microenvironment.
- 8 February 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1332781
Open AccessCD34+DNAM-1brightCXCR4+ haemopoietic precursors circulate after chemotherapy, seed lung tissue and generate functional innate-like T cells and NK cells
Background: There is little information on the trajectory and developmental fate of Lin-CD34+DNAM-1bright CXCR4+ progenitors exiting bone marrow during systemic inflammation.Objective: To study Lin-CD34+DNAM-1bright CXCR4+ cell circulation in cancer patients, to characterize their entry into involved lung tissue and to characterize their progenies.Methods: Flow cytometric analysis of PBMC from 18 patients with lung cancer on samples collected immediately before the first and the second treatment was performed to study Lin-CD34+DNAM-1bright CXCR4+ precursors. Precursors were purified (>99%) and cultured in vitro from all patients. Paired PBMC and tissue samples from patients undergoing tumor resection were analyzed by flow cytometry to assess tissue entry and compare phenotype and developmental potential of Lin-CD34+DNAM-1bright CXCR4+ cells in both compartments.Results: Significant circulation of Lin-CD34+DNAM-1bright CXCR4+ precursors was observed 20d after the first treatment. Precursors express CXC3CR1, CXCR3, CXCR1 consistent with travel towards inflamed tissues. Flowcytometric analysis of lung tissue samples showed precursor presence in all patients in tumor and neighboring uninvolved areas. Successful purification and in vitro culture from both blood and lung tissue generates a minor proportion of maturing NK cells (85%) of α/β T-progenies with innate-like phenotype expressing NKG2D,NKp30,DNAM-1. Innate-like maturing T-cells in vitro are cytotoxic, can be triggered via NKR/TCR co-stimulation and display broad spectrum Th1,Th2 and Th1/Th17 cytokine production.Conclusion: In advanced stage lung cancer CD34+DNAM-1brightCXCR4+ inflammatory precursors increase upon treatment, enter involved tissues, generate functional progenies and may thus represent an additional player contributing to immune balance in the highly SDF-1/CXCR4-biased pro-metastatic tumor microenvironment.
- Open Access
- 19 December 2022
- Published by Elsevier in Seminars in Immunology
- Vol. 65, 101706
Adaptive NK cell response to human cytomegalovirus: Facts and open issues
- 19 December 2022
- Published by Elsevier in Seminars in Immunology
- Vol. 65, 101706
Open AccessAdaptive NK cell response to human cytomegalovirus: Facts and open issues
- Open Access
Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity
In recent years, immunotherapy has become a powerful therapeutic option against multiple malignancies. The unique capacity of natural killer (NK) cells to attack cancer cells without antigen specificity makes them an optimal immunotherapeutic tool for targeting tumors. Several approaches are currently being pursued to maximize the anti-tumor properties of NK cells in the clinic, including the development of NK cell expansion protocols for adoptive transfer, the establishment of a favorable microenvironment for NK cell activity, the redirection of NK cell activity against tumor cells, and the blockage of inhibitory mechanisms that constrain NK cell function. We here summarize the recent strategies in NK cell-based immunotherapies and discuss the requirement to further optimize these approaches for enhancement of the clinical outcome of NK cell-based immunotherapy targeting tumors.
Open AccessNext Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity
In recent years, immunotherapy has become a powerful therapeutic option against multiple malignancies. The unique capacity of natural killer (NK) cells to attack cancer cells without antigen specificity makes them an optimal immunotherapeutic tool for targeting tumors. Several approaches are currently being pursued to maximize the anti-tumor properties of NK cells in the clinic, including the development of NK cell expansion protocols for adoptive transfer, the establishment of a favorable microenvironment for NK cell activity, the redirection of NK cell activity against tumor cells, and the blockage of inhibitory mechanisms that constrain NK cell function. We here summarize the recent strategies in NK cell-based immunotherapies and discuss the requirement to further optimize these approaches for enhancement of the clinical outcome of NK cell-based immunotherapy targeting tumors.
- Open Access
- 19 March 2022
- Published by Springer Nature in European Journal of Medical Research
- Vol. 27 (1) , 1-4
Mind the gap: IgG4-related disease mimicking infectious cerebral mass lesions
Background: Cerebral intraparenchymal masses represent usually a neoplastic, or infectious differential diagnostic workup in neurology or infectious disease units. Case presentation: Our patient was an 82-year-old male presenting with seizures, cerebral masses and a history of past treated pulmonary tuberculosis. Initial workup included a differential diagnosis of an infectious mass/multiple abscess. After exclusion of infectious or primary neoplastic origins by negative HIV serology, the absence of immune suppression, endocarditic lesions, negative results of blood cultures and bronchoalveolar lavage, negative cerebrospinal fluid workout on spinal tap led to exclusion of infectious causes. A surgical procedure was performed to access one of the lesions. This yielded a firm, cyst-like mass of histiocytic granulomatous tissue with a conspicuous plasmacellular component and a relevant IgG4 plasmacellular component consistent with IgG4-related disease. Steroid treatment determined conspicuous improvement and led to discharge of the patient. Conclusion: Parenchymal IgG4-related disease may be included as a new entity in the differential diagnosis of single or multiple cerebral masses in addition to infectious or neoplastic etiology.
- 19 March 2022
- Published by Springer Nature in European Journal of Medical Research
- Vol. 27 (1) , 1-4
Open AccessMind the gap: IgG4-related disease mimicking infectious cerebral mass lesions
Background: Cerebral intraparenchymal masses represent usually a neoplastic, or infectious differential diagnostic workup in neurology or infectious disease units. Case presentation: Our patient was an 82-year-old male presenting with seizures, cerebral masses and a history of past treated pulmonary tuberculosis. Initial workup included a differential diagnosis of an infectious mass/multiple abscess. After exclusion of infectious or primary neoplastic origins by negative HIV serology, the absence of immune suppression, endocarditic lesions, negative results of blood cultures and bronchoalveolar lavage, negative cerebrospinal fluid workout on spinal tap led to exclusion of infectious causes. A surgical procedure was performed to access one of the lesions. This yielded a firm, cyst-like mass of histiocytic granulomatous tissue with a conspicuous plasmacellular component and a relevant IgG4 plasmacellular component consistent with IgG4-related disease. Steroid treatment determined conspicuous improvement and led to discharge of the patient. Conclusion: Parenchymal IgG4-related disease may be included as a new entity in the differential diagnosis of single or multiple cerebral masses in addition to infectious or neoplastic etiology.
- 3 March 2022
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 386 (9) , 897-899
Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination
Murphy and Longo (published online on Nov. 24 at NEJM.org)1 elaborate on the possible role played by anti-idiotype antibodies in the pathogenesis of severe adverse reactions to SARS-CoV-2 infection and vaccination, mentioning only myocarditis and immune-mediated thrombosis and thrombocytopenia.
- 3 March 2022
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 386 (9) , 897-899
Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination
Murphy and Longo (published online on Nov. 24 at NEJM.org)1 elaborate on the possible role played by anti-idiotype antibodies in the pathogenesis of severe adverse reactions to SARS-CoV-2 infection and vaccination, mentioning only myocarditis and immune-mediated thrombosis and thrombocytopenia.
- Open Access
- 4 February 2022
- Published by MDPI AG in Microorganisms
- Vol. 10 (2) , 362
Reactivation of Herpes Simplex Virus Type 1 (HSV-1) Detected on Bronchoalveolar Lavage Fluid (BALF) Samples in Critically Ill COVID-19 Patients Undergoing Invasive Mechanical Ventilation: Preliminary Results from Two Italian Centers
Reactivation of herpes simplex virus type 1 (HSV-1) has been described in critically ill patients with coronavirus disease 2019 (COVID-19) pneumonia. In the present two-center retrospective experience, we primarily aimed to assess the cumulative risk of HSV-1 reactivation detected on bronchoalveolar fluid (BALF) samples in invasively ventilated COVID-19 patients with worsening respiratory function. The secondary objectives were the identification of predictors for HSV-1 reactivation and the assessment of its possible prognostic impact. Overall, 41 patients met the study inclusion criteria, and 12/41 patients developed HSV-1 reactivation (29%). No independent predictors of HSV-1 reactivation were identified in the present study. No association was found between HSV-1 reactivation and mortality. Eleven out of 12 patients with HSV-1 reactivation received antiviral therapy with intravenous acyclovir. In conclusion, HSV-1 reactivation is frequently detected in intubated patients with COVID-19. An antiviral treatment in COVID-19 patients with HSV-1 reactivation and worsening respiratory function might be considered.
- 4 February 2022
- Published by MDPI AG in Microorganisms
- Vol. 10 (2) , 362
Open AccessReactivation of Herpes Simplex Virus Type 1 (HSV-1) Detected on Bronchoalveolar Lavage Fluid (BALF) Samples in Critically Ill COVID-19 Patients Undergoing Invasive Mechanical Ventilation: Preliminary Results from Two Italian Centers
Reactivation of herpes simplex virus type 1 (HSV-1) has been described in critically ill patients with coronavirus disease 2019 (COVID-19) pneumonia. In the present two-center retrospective experience, we primarily aimed to assess the cumulative risk of HSV-1 reactivation detected on bronchoalveolar fluid (BALF) samples in invasively ventilated COVID-19 patients with worsening respiratory function. The secondary objectives were the identification of predictors for HSV-1 reactivation and the assessment of its possible prognostic impact. Overall, 41 patients met the study inclusion criteria, and 12/41 patients developed HSV-1 reactivation (29%). No independent predictors of HSV-1 reactivation were identified in the present study. No association was found between HSV-1 reactivation and mortality. Eleven out of 12 patients with HSV-1 reactivation received antiviral therapy with intravenous acyclovir. In conclusion, HSV-1 reactivation is frequently detected in intubated patients with COVID-19. An antiviral treatment in COVID-19 patients with HSV-1 reactivation and worsening respiratory function might be considered.
- 1 June 2021
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 147 (6) , 2343-2357
HCMV-controlling NKG2C+ NK cells originate from novel circulating inflammatory precursors
- 1 June 2021
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 147 (6) , 2343-2357
HCMV-controlling NKG2C+ NK cells originate from novel circulating inflammatory precursors
- Open Access
- 29 April 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (9) , 5608-5613
Characterization of T lymphocytes in severe COVID‐19 patients
In this observational study, 13 patients with severe COVID‐19 and 10 healthy controls were enrolled. The data concerning the analysis of circulating T cells show that, in severe COVID‐19 patients, the expansion of these cell compartments is prone to induce antibody response, inflammation (CCR4+ and CCR6+ TFH) and regulation (CD8+ Treg). This pathogenic mechanism could lead us to envision a possible new form of biological target therapy.
- 29 April 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (9) , 5608-5613
Open AccessCharacterization of T lymphocytes in severe COVID‐19 patients
In this observational study, 13 patients with severe COVID‐19 and 10 healthy controls were enrolled. The data concerning the analysis of circulating T cells show that, in severe COVID‐19 patients, the expansion of these cell compartments is prone to induce antibody response, inflammation (CCR4+ and CCR6+ TFH) and regulation (CD8+ Treg). This pathogenic mechanism could lead us to envision a possible new form of biological target therapy.